Want to see BCAB full AI Analyst Report?
Top Page
BioAtla
(OTC:BCAB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-52.23% Downside)
Action:Reiterated
Date:10/20/26
BCAB scores low primarily due to weak financial performance (continued losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support given a negative P/E and no dividend, and corporate events add meaningful downside risk via delisting/OTC trading despite improved financing access.
Positive Factors
CAB technology platform
BioAtla’s proprietary CAB platform provides a differentiated scientific basis for developing oncology therapeutics that may improve tumor targeting and tolerability. If clinical work validates these design goals, the technology could support a pipeline with reusable development potential across multiple cancer indications.
Negative Factors
Negative stockholders’ equity
Negative equity signals a severely weakened capital base and limits financial flexibility. Alongside declining assets, it raises the likelihood that BioAtla must rely on external capital to fund operations, increasing exposure to dilution and making it harder to absorb setbacks in development or financing conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
CAB technology platform
BioAtla’s proprietary CAB platform provides a differentiated scientific basis for developing oncology therapeutics that may improve tumor targeting and tolerability. If clinical work validates these design goals, the technology could support a pipeline with reusable development potential across multiple cancer indications.
Read all positive factors
BioAtla (BCAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.85M
Dividend YieldN/A
Average Volume (3M)14.57K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth-22.73%
EPS Growth53.53%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-25.45
Shares Outstanding1,668,261
10 Day Avg. Volume4,964
30 Day Avg. Volume14,572
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap3.93
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.32
Enterprise Value/Ebitda-0.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
BioAtla Business Overview & Revenue Model
Company Description
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeu...
BioAtla Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials, strategic transactions, and market potential for BioAtla's programs, with robust data supporting their CAB platform's potential. However, financial challenges were noted, including increased net loss and decreased cash reserves.Positive Updates
FDA Alignment on Phase Three Trial Design
BioAtla achieved FDA alignment on the phase three OSV registrational trial design for OPSCC, which includes a dual primary endpoints design for potential accelerated approval followed by full approval.
Negative Updates
Increased Net Loss
Reported a net loss of $15.8 million for the third quarter of 2025, compared to a net loss of $10.6 million in the same quarter of 2024, primarily due to collaboration revenue recorded in 2024 and a non-cash loss on warrant liability in 2025.
Read all updates
Q3-2025 Updates
Positive
Negative
FDA Alignment on Phase Three Trial Design
BioAtla achieved FDA alignment on the phase three OSV registrational trial design for OPSCC, which includes a dual primary endpoints design for potential accelerated approval followed by full approval.
Read all positive updates
Company Guidance
During BioAtla, Inc.'s third quarter 2025 earnings call, the company provided several key metrics and updates. They are in advanced stages of finalizing a strategic transaction with a potential partner by year-end. The FDA has aligned with their phase three OSV registrational trial design for second-line plus oropharyngeal squamous cell carcinoma (OPSCC), targeting dual primary endpoints of overall response rate and overall survival, with potential for accelerated approval. The estimated worldwide peak sales for their OSFI product in second-line OPSCC alone are approximately $800 million, with the total OPSCC market projected to reach $3 billion by 2032. They reported a net loss of $15.8 million for the quarter, an increase from a $10.6 million net loss in the same quarter of 2024. BioAtla, Inc. had $8.3 million in cash and cash equivalents as of September 30, 2025, and expects R&D expenses to decline as they concentrate resources on prioritized programs.BioAtla Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.50M | 2.00M | 11.00M | 0.00 | 0.00 | 250.00K |
| Gross Profit | 8.50M | -41.07M | 10.07M | -1.22M | -1.20M | -58.02M |
| EBITDA | -31.75M | -59.23M | -68.85M | -122.24M | -105.28M | -94.07M |
| Net Income | -31.45M | -59.61M | -69.78M | -123.46M | -105.28M | -95.40M |
Balance Sheet | ||||||
| Total Assets | 9.51M | 13.83M | 52.42M | 119.66M | 225.74M | 254.42M |
| Cash, Cash Equivalents and Short-Term Investments | 1.54M | 7.12M | 49.05M | 111.47M | 215.51M | 244.98M |
| Total Debt | 5.86M | 6.20M | 836.00K | 2.46M | 3.98M | 5.37M |
| Total Liabilities | 45.74M | 50.02M | 38.16M | 48.99M | 45.40M | 43.60M |
| Stockholders Equity | -36.24M | -36.19M | 14.27M | 70.67M | 180.34M | 210.82M |
Cash Flow | ||||||
| Free Cash Flow | -23.48M | -48.20M | -71.94M | -104.11M | -90.69M | -63.14M |
| Operating Cash Flow | -23.48M | -48.20M | -71.94M | -104.02M | -90.42M | -62.21M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -98.00K | -265.00K | -924.00K |
| Financing Cash Flow | 6.82M | 6.28M | 9.51M | 77.00K | 61.21M | 69.51M |
BioAtla Technical Analysis
Neutral
3.14
Price Trends
1.80
Negative
2.72
Negative
5.45
Negative
Market Momentum
-0.10
Negative
55.99
Neutral
44.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCAB, the sentiment is Neutral. The current price of 3.14 is above the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.80, and below the 200-day MA of 5.45, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 55.99 is Neutral, neither overbought nor oversold. The STOCH value of 44.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BCAB.
BioAtla Risk Analysis
BioAtla disclosed 91 risk factors in its most recent earnings report. BioAtla reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAtla Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $47.79M | 4.22 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $264.37M | -1.40 | -52.76% | ― | -100.00% | -219.52% | |
44 Neutral | $71.00M | -1.81 | -211.15% | ― | ― | -7.28% | |
43 Neutral | $2.85M | -0.07 | 89.25% | ― | -22.73% | 53.53% | |
41 Neutral | $9.49M | -0.39 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
BCAB
BioAtla
1.71
-36.29
-95.50%
ATNM
Actinium Pharmaceuticals
1.52
-0.15
-8.98%
LTRN
Lantern Pharma
0.64
-3.45
-84.44%
IPSC
Century Therapeutics
1.46
0.88
153.03%
MAIA
MAIA Biotechnology, Inc.
1.15
-0.28
-19.58%
BioAtla Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
BioAtla Expands Equity Financing with New Yorkville Agreement
Positive
Oct 20, 2026
On October 15, 2026, BioAtla entered into a new Standby Equity Purchase Agreement with Yorkville, giving the company the option to sell up to $40 million of common stock over 36 months, with sales priced at a discount to market VWAP and subject to...
Business Operations and StrategyExecutive/Board Changes
BioAtla announces CMO resignation amid capital-raising focus
Neutral
Sep 29, 2026
On September 25, 2026, BioAtla’s Chief Medical Officer, Dr. Eric Sievers, resigned to pursue opportunities outside the company but agreed to remain as a consultant through June 30, 2027, with his compensation tied to hours worked and the ach...
Business Operations and StrategyDelistings and Listing Changes
BioAtla Faces Nasdaq Delisting, Plans OTC Market Move
Negative
Aug 28, 2026
On February 6, 2026, BioAtla received notice that a Nasdaq Hearings Panel had determined to suspend and delist its securities for failing to meet the $1.00 minimum bid price and the $2.5 million stockholders’ equity requirements, despite pri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.